Evidence map›Paper›PMID 39162528›Full record

ArticleAntimicrobial agents and chemotherapy2024

A molecular analysis of meropenem-vaborbactam non-susceptible KPC-producing

Mohamad Yasmin, Steven H Marshall, Liang Chen, Daniel D Rhoads, Michael R Jacobs, Laura J Rojas, Federico Perez, Andrea M Hujer, Kristine M Hujer, David van Duin and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. KPC-producing Klebsiella pneumoniae in Switzerland from 2024 to 2025: comparative genomics and cefiderocol resistance mechanisms analyses.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  2. Emergence of KPC-producingAntimicrobial agents and chemotherapy · 2026
    Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mohamad YasminLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.ORCID 0000-0002-5859-1769
Steven H MarshallLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Liang ChenCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.ORCID 0000-0001-5845-2235
Daniel D RhoadsDepartment of Pathology, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA.ORCID 0000-0002-7636-5191
Michael R JacobsDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0002-4235-7855
Laura J RojasLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.ORCID 0000-0003-4410-1658
Federico PerezLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Andrea M HujerLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Kristine M HujerLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
David van DuinDepartment of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0003-4784-3227
Vance FowlerDuke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Henry F ChambersDepartment of Medicine, University of California San Francisco, San Francisco, California, USA.
Barry N KreiswirthCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.ORCID 0000-0002-0243-131X
Robert A BonomoLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.ORCID 0000-0002-3299-894X
Antibacterial Resistance Leadership Group

Funding

Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8M
The J. Craig Venter Institute Genome Center for Infectious DiseasesU19AI110819 · NIAID · J. CRAIG VENTER INSTITUTE, INC. · PI NELSON, KAREN E., NIERMAN, WILLIAM CHARLES · 2014 to 2018
$29.7M
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) U19AI110819HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) UM1AI104681NIAID NIH HHS U19 AI110819NIAID NIH HHS UM1 AI104681
6 · The paper itself

Abstract

We characterized the molecular determinants of meropenem-vaborbactam (MV) non-susceptibility among non-metallo-β-lactamase-producing KPC-

Indexed as

Anti-Bacterial AgentsBacterial Proteinsbeta-LactamasesBoronic AcidsKlebsiella pneumoniaeMeropenemMicrobial Sensitivity TestsWhole Genome SequencingDrug CombinationsDrug Resistance, Multiple, BacterialHeterocyclic Compounds, 1-RingHumansKlebsiella InfectionsMutationPorinsAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesBoronic AcidsDrug CombinationsHeterocyclic Compounds, 1-RingMeropenemmeropenem and vaborbactamOmpK36 protein, Klebsiella pneumoniaePorinsvaborbactamantimicrobial resistanceKlebsiella pneumoniae carbapenemasemeropenemmeropenem vaborbactam resistanceOmpK35OmpK36Vabomere resistancevaborbactam

Identifiers

PMID39162528
PMCPMC11459940

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.